Pharmacological inhibition of the JAK2/STAT3 pathway in Pten-deficient senescent prostate tumors modified SASP composition, leading to an anti-tumor immune response that enhances chemotherapy efficacy [187]. This evidence concerns the gene PTEN and neoplasm.